Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by MML Investors Services LLC

MML Investors Services LLC reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 9.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,943 shares of the medical equipment provider's stock after selling 3,623 shares during the period. MML Investors Services LLC's holdings in Zimmer Biomet were worth $3,585,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Roman Butler Fullerton & Co. bought a new position in shares of Zimmer Biomet during the 4th quarter valued at approximately $473,000. KLCM Advisors Inc. purchased a new stake in Zimmer Biomet during the fourth quarter valued at $7,825,000. Peddock Capital Advisors LLC bought a new position in Zimmer Biomet during the fourth quarter valued at $654,000. Van ECK Associates Corp grew its stake in shares of Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after buying an additional 218,688 shares in the last quarter. Finally, Reinhart Partners LLC. increased its holdings in shares of Zimmer Biomet by 34.4% in the 4th quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider's stock worth $9,164,000 after buying an additional 22,220 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.95% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ZBH. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. JMP Securities restated a "market outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Raymond James dropped their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Royal Bank of Canada decreased their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Stock Down 1.1 %

Shares of ZBH stock traded down $1.12 during mid-day trading on Thursday, hitting $101.94. 747,991 shares of the stock traded hands, compared to its average volume of 1,663,903. The stock's fifty day moving average is $105.72 and its two-hundred day moving average is $106.55. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a 52-week low of $93.10 and a 52-week high of $123.96. The stock has a market cap of $20.17 billion, a P/E ratio of 22.96, a P/E/G ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company earned $2.20 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were given a $0.24 dividend. The ex-dividend date was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.94%. Zimmer Biomet's dividend payout ratio is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.